Markets:

Overview

News

Currencies

International

Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

1.439 -0.041 (-2.77%)

Streaming Delayed Price Updated: 12:13 PM EDT, Aug 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ProKidney Corp. - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

AZZ Posts Better-Than-Expected Earnings, Joins MP Materials, WK Kellogg And Other Big Stocks Moving Higher On Thursday ↗

July 10, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

July 10, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

July 10, 2025

Via Benzinga

Which stocks are most active on Wednesday? ↗

July 09, 2025

Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.

Via Chartmill

Which stocks have an unusual volume on Wednesday? ↗

July 09, 2025

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Via Chartmill

These stocks are moving in today's session ↗

July 09, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results ↗

July 09, 2025

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday driven by positive clinical trial data for its CKD treatment.

Via Benzinga

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗

July 09, 2025

Via Benzinga

Which stocks are gapping on Wednesday? ↗

July 09, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

These stocks are moving in today's pre-market session ↗

July 09, 2025

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 09, 2025

Via Benzinga

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

July 09, 2025

From ProKidney

Via GlobeNewswire

US Stocks Likely To Open Higher: Trump's Tariff Clock Ticks, Fed Likely To Keep Rates Unchanged ↗

July 09, 2025

U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were trading higher.

Via Benzinga

Topics Economy Government

Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

July 09, 2025

Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest.

Via Benzinga

ProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of Success ↗

July 09, 2025

The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3...

Via Stocktwits

Dow Tumbles Over 150 Points Amid Trump Tariffs: Investor Sentiment Declines, Fear Index Moves To 'Greed' Zone ↗

July 09, 2025

Via Benzinga

Topics Government Stocks

ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday ↗

July 08, 2025

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours to $4.05 on positive Phase 2 trial results, with trading volume seeing a...

Via Benzinga

Prokidney, Soundhound AI, Quantumscape, Intel, And Nvidia: Why These 5 Stocks Are On Investors' Radars Today ↗

July 08, 2025

U.S. major indices ended mixed on Tuesday, as the Dow Jones Industrial Average slipped nearly 0.4% to 44,240.76 and the S&P 500 edged down 0.1% to 6,225.52.

Via Benzinga

Topics Artificial Intelligence Stocks

Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz ↗

July 08, 2025

Via The Motley Fool

Topics Stocks

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 08, 2025

Via Benzinga

Most active stocks in Tuesday's session ↗

July 08, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.

Via Chartmill

Gold Falls 1%; ProKidney Shares Spike Higher ↗

July 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 08, 2025

Via Benzinga

Gapping stocks in Tuesday's session ↗

July 08, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

US Stocks Mixed; Small Business Sentiment Falls In June ↗

July 08, 2025

Via Benzinga

Why Is Penny Stock ProKidney Trading Higher On Tuesday? ↗

July 08, 2025

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with chronic kidney disease and diabetes.

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

July 08, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 08, 2025

Via Benzinga

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

July 08, 2025

From ProKidney

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.